The influence of testosterone suppression and recovery on sexual function in men with prostate cancer: observations from a prospective study in men undergoing intermittent androgen suppression

What Was Tested

This clinical trial, phase ii paper looks at Leuprolide in the context of sexual function & libido (women and men).

The researchers investigated the effects of testosterone change on the sexual function of men with prostate cancer undergoing intermittent maximal androgen deprivation therapy.

Who Took Part

According to the abstract, 250 patients were involved.

PubMed indexes the participants as older adults and people over 80, men only.

The researchers conducted a phase II cohort study of 250 patients with prostate cancer undergoing intermittent maximal androgen deprivation therapy.

Monitoring continued every 3 months for a further 2 years (OFFPhase) unless re-treatment occurred.

How the Study Was Run

Therapy was ceased provided that prostate specific antigen was 4 ng/ml or less.

Sexual function was assessed with the QLQ-PR25 version 3.0 prostate module in conjunction with the QLQ-C30 questionnaire at baseline and every 3 months thereafter.

What Was Measured

The subject headings attached to it are Androgen Antagonists, Antineoplastic Agents, Hormonal, Biomarkers, Tumor, Flutamide, Leuprolide, Libido and Masculinity.

What This Means in Plain Language

This is a clinical trial, phase ii of Leuprolide in 250 patients in people with sexual function & libido (women and men).

The abstract goes on to report its results in about 12 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2012 (The Journal of urology), a journal based in United States.

More context: the Leuprolide compound page, Sexual function & libido (women and men) research.